Numerous studies have demonstrated the participation of sphingolipids in signal transduction and the regulation of cell growth and apoptosis. [1] [2] [3] We are continuing attempts to elucidate the biological function of glycosphingolipids (GSLs) found in various invertebrates that do not have sialic acids. 4) With the aim of discovering new anticancer drugs, we have synthesized ten glycolipids found in invertebrates not having sialic acids. Malignant melanoma is very difficult to cure because of its rapid growth, metastasis, and resistance to chemotherapy.
With the aim of discovering new anticancer drugs, we have synthesized ten glycolipids found in invertebrates not having sialic acids. Malignant melanoma is very difficult to cure because of its rapid growth, metastasis, and resistance to chemotherapy. 5) Many therapeutic approaches to suppress melanoma growth and metastasis have been attempted. 5) Therefore, drugs inhibiting the proliferation of melanoma cells would be of great value. Hess et al. reported that focal adhesion kinase (FAK) increased invasion and migration in aggressive human melanoma cells. 6) They found FAK to be phosphorylated and activated in these cells. 6 ) Downstream of FAK signaling molecules are phosphatidyliositol 3-kinase (PI3-kinase)-protein kinase B (PKB/Akt) and extracellular signal-regulated kinase (Erk). In previous reports, Erk and Akt pathways were activated in B16 melanoma cells. [7] [8] [9] [10] Further, Davies et al. detected B-raf somatic missense mutations in 60-70% of melanoma cell lines and that the Erk and Akt signaling pathways are constitutively activated. 11) Both these pathways are known to be critically important for cell growth. Furthermore, dominant negative FAK mutants suppressed the metastatic growth of B16F10 cells by downregulating cell proliferation. 12) From these reports, FAK and the downstream signal molecules, Erk and Akt, might be targets in the treatment of melanoma. In this paper, we report that glycosphingolipid 7 suppressed cell proliferation and that this effect was associated with suppression of the activation of FAK, Erk, and Akt in melanoma B16F10 cells.
MATERIALS AND METHODS

Cells and Reagents
A mouse melanoma cell line, B16F10 was obtained from Prof. Yoshikazu Sugimoto (Kyoritsu University of Pharmacy) and maintained in Dulbecco's modified Eagle's medium (Nissui Seiyaku, Tokyo) supplemented with 5% heat-inactivated fetal calf serum (FCS, Nippon Bio-Supply Center, Tokyo).
Glycolipids 1-10 were synthesized as described previously [13] [14] [15] [16] and dissolved in DMSO to give a stock solution of 50 mM. The stock solution was stored for up to 1 month at 4°C. On the day of experiments, dilutions were made by diluting with incubation medium to 0.5 mM (final DMSO concentration, 1%). Further dilutions were made in medium containing 1% DMSO solvent. Antibodies (Abs) against actin, cyclin D1, 2, and 3, CDK2, and CDK4 were purchased from Santa Cruz Biotechnology (CA, U.S.A.). Antibodies (Abs) against phosphotyrosine (PY) and FAK were purchased from Transduction Lab (KY, U.S.A.), and Abs against Y397-phospho-FAK, pRb and Ser788-, Ser795-, Ser807/811-phosphopRb were from Cell Signaling (MA, U.S.A.). Enhanced chemiluminescence reagents were obtained from GE Healthcare Bio-Sciences (Piscataway, NJ, U.S.A.).
Cell Growth and Its Evaluation Exponentially growing melanoma cells were harvested and plated (2000 per well in a volume of 90 ml) in 96-well plates and incubated at 37°C for 3 h. Each glycolipid was then added (10 ml of 1% DMSOcontaining medium) to the wells to give a final volume of 100 ml/well (final concentration of DMSO, 0.1%). Control wells contained 10 ml of medium containing 1% DMSO (final concentration of DMSO, 0.1%). After cells were incubated for 72 h, cell numbers were determined by both the trypan blue (TB) dye exclusion method and a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
Lactate Dehydrogenase (LDH) Assay Melanoma cells were seeded at a density of 2000 cells/well in 90 ml of culture medium in a 96-well plate. Glycosphingolipid 7 (10 ml of 1% DMSO-containing medium) was added to the medium at the appropriate concentrations. The level of LDH activity released in the medium was measured by using the LDH-cytotoxic kit (Wako Pharmaceutical Co., Tokyo).
Immunoblotting Immunoblotting was done as described previously. 17, 18) In brief, cells were plated onto 24-well cell culture plates (20000 cells in 0.9 ml). After 3 h, 0.1 ml of glycolipid (final concentration of DMSO, 0.1%) was added and incubated for the periods described. Next, 20 mg of total protein from the whole cell lysate was boiled in Laemmli buffer and loading onto SDS-PAGE mini gels. The proteins were transferred to nitrocellulose membranes, subjected to blocking treatment with 3% BSA in PBS for 1 h, and then incubated with the primary Ab for 1 h at room temperature followed by the secondary Ab coupled to horseradish peroxidase, before being detected using an enhanced chemiluminescene system.
Immunoprecipitation The immunoprecipitation analysis was conducted as described previously. 17, 18) In brief, harvested cells were lysed in lysis buffer on ice and cleaned by centrifugation to obtain whole cell extracts. Aliquots (250 mg) of cell lysate were mixed with Protein G-Sepharose (Pharmacia-LKB Biotechnologies; Uppsala, Sweden) and anti-FAK Ab overnight at 4°C. The immune complexes were precipitated by centrifugation, washed five times with lysis buffer and boiled in Leammli sample buffer. Boiled samples were separated by SDS-PAGE and the proteins transferred to nitrocellulose membranes. Immunoblotting was performed with anti-rabbit IgG antibody-conjugated horseradish peroxidase, and visualized using an enhanced chemiluminescence immunoblotting detection system.
Data Analysis Experiments were repeated at least three times and data were calculated as meansϮS.D. Statistical comparisons were carried out using a Students t-test. A p value less than 0.05 was considered significant.
RESULTS
Glycosphingolipid 7 Inhibits the Proliferation of B16 Melanoma Cells
We synthesized compounds 1-10 as shown in Fig. 1 . [13] [14] [15] [16] The origins of these compounds are as follows: Compounds 1-4 are glycosphingolipids from the parasite Echinococcus multilocularis. 19) Compounds 5 and 6 are glycosphingolipids from the crab Erimacrus isenbeckii. 20) Amphoteric mono-and disaccharide 8 and 9 containing fatty alkyl residues in place of ceramide are derivatives of glycolipids from the earthworm Pheretima hilgendorfi. 21) Pentasaccharide 10 is a derivative of the glycolipids from the parasite Spirometra erinacei. 22) Compound 7 is a glycosphingolipid from the periodical millipede Parafontaria laminata armigera. 23) Compounds 1-4 have a dihydroceramide skeletal structure. Compounds 5, 6, and 7 have a ceramide skeletal structure. Compounds 8-10 have no ceramide structure. First, we analyzed the effect of these glycolipids on the proliferation of melanoma cells by using a MTT assay. Several concentrations of these glycolipids were tested, and the results at 50 mM are shown in Fig. 2A . We observed that glycosphingolipid 7 was the most effective suppressor of proliferation. Glycophingolipids 1-4 did not show any antiproliferative effects at up to 50 mM. From these results, the ceramide structure might be required for antiproliferative activity. Glycosphingolipids 5 and 6 having a ceramide structure showed moderate antiproliferative activity, suggesting that the ceramide structure and the Manb(1-4)[Fuca(1-3)]Glcb1 link-age structure are most suitable for the antiproliferative activity. Amphoteric monosaccharide 8 accelerated the proliferation. The action of 8 should be studied in future. Next, we examined the mechanism of the antiproliferative effect of glycosphingolipid 7. The dose-dependent antiproliferative effect of glycosphingolipid 7 on melanoma cells is shown in Fig. 2B (IC 50 , 50 mM) . The IC 50 values of the other compounds were Ͼ70 mM (data not shown). To evaluate whether the reduced number of viable cells in the MTT assay was due to cell death or to growth inhibition, we determined the cytotoxicity of glycosphingolipid 7 in melanoma cells. Cell viability was evaluated by the trypan blue exclusion (TB) method and LDH release assay. The cell viability (Ͼ90%) of glycosphingolipid 7-treated cells determined by the TB method was the same as that of untreated cells (data not shown). The level of LDH activity released in the medium in glycosphingolipid 7-treated cells was the same as that of untreated cells (cytotoxicity, Ͻ5%). These results suggest that the decrease in number in glycosphingolipid 7-treated cells was caused by growth inhibition.
Inhibition of FAK-Akt and Erk1/2 Activation Is Involved in Inhibition of Melanoma Proliferation by Glycosphingolipid 7
Since glycosphingolipid 7 was effective at inhibiting the proliferation of melanoma cells, we studied whether it affects the signaling pathway. We investigated the activation of receptor tyrosine kinase (RTK) and the intracellular pathway activated by RTK as well as mitogen-activated protein kinase (MAPK) and the FAK/Akt pathway. 17, 18) In human melanoma cells, FAK and the downstream signaling pathway are constitutively activated. 7) We focused on the activation of FAK and the downstream signaling, since FAK exists downstream of various RTKs, such as EGFR and integrin. 24) We assumed that glycosphingolipid 7 affects FAK and the downstream signaling. First, to find the site of inhibition of those intracellular pathways in melanoma cells, we examined the tyrosine phosphorylation after stimulation with glycosphingolipid 7 using anti-PY MAb. As shown in Fig.  3A , untreated cells showed various bands of tyrosine phosphorylated proteins. When the cells were treated with 50 mM glycosphingolipid 7, the intensity of the ca. 120 kDa band was decreased. The ca. 120 kDa protein was speculated to be FAK with a MW of 125 kDa. To confirm this notion, immunoprecipitation (IP) and sequential immunoblotting (IB) were performed. We identified the band of 120 kDa as FAK by IP with anti-FAK Ab, followed by blotting with anti-PY MAb. From these results, we presumed that the FAK-PI3-kinase-Akt pathway was activated in untreated cells and inhibited by the treatment with glycosphingolipid 7 in melanoma cells. Although FAK has many tyrosine phosphorylation sites, such as 397, 576, 577, 861, and 925, at least 397Y was phosphorylated in untreated cells as shown in Fig. 3B . The phosphorylation of 397Y was inhibited by the treatment with glycosphingolipid 7. Next, we examined the serine phosphorylation of Akt, a downstream signal molecule of FAK, using anti-phospho-Akt Ab. As expected, the phosphorylation of Akt was observed in untreated cells and inhibited by the treatment with glycosphingolipid 7 (Fig. 3C) . These results indicated that glycosphingolipid 7 suppressed the activation of the Akt pathway via FAK's activation. As Erk1/2 is a downstream signal molecule of FAK, we examined the activation of Erk1/2 in melanoma cells using phospho-Erk1/2 Ab. The phosphorylation of Erk1/2 was observed in untreated melanoma cells, and inhibited by the treatment with glycosphingolipid 7 at 50 mM as shown in Fig. 3C .
Cyclin D1 Expression Was Downregulated by Glycosphingolipid 7 The effect of Akt on cell proliferation has been related to cell cycle proteins including p27, p21 and cyclin D. 25) Furthermore, Erk has been suggested to induce the expression of cyclin D1 and CDK4.
26) Therefore, we tested whether glycosphingolipid 7 alters the expression of these cell cycle proteins. The expression of cyclin D1 and CDK-4 was found to be decreased by glycosphingolipid 7 (Fig. 4) . The expression of p21 was not changed. No significant changes to the other cell cycle-related proteins, cyclin D2, 3, CDK2, and p27, were found (data not shown).
Decreased Rb Phosphorylation Cyclin D1 is associated with CDK4/6 and phosphorylates Rb protein, which plays a critical role in the G1 to S transition. 26) The association of Rb with a transcription factor, E2F, is thought to block passage through the G1 checkpoint. Phosphorylated Rb then disassociates E2F, which allows the progression of cells into S phase. 27) We assumed that the phosphorylation of Rb is suppressed in glycosphingolipid 7-treated cells. To determine the state of pRb phosphorylation in glycosphingolipid 7-treated melanoma cells, we analyzed the phosphorylation of pRb, a substrate of cyclin D/CDK4, and cyclin E/CDK2 kinase complexes. While pRb has 16 potential phosphorylation sites, we examined the phosphorylation of Ser788, Ser795, and Ser807/811 using a specific antibody for immunoblotting, and found that two or three sites, Ser788 and Ser807/811, were highly phosphorylated in control cells. In glycosphingolipid 7-treated melanoma cells, we observed decreased phosphorylation of Ser788 and Ser807/811.
DISCUSSION
We observed that the proliferation of melanoma cells was inhibited by glycosphingolipid 7 among various sphingolipids tested so far. The glycolipids 5 and 6 having a ceramide structure showed moderate inhibitory effects on melanoma cell proliferation. Glycolipid 10 with partial common sugars also had moderate inhibitory effects. We assume that the structure of ceramide and Manb (1) (2) (3) (4) [Fuca(1-3)]-Glcb1 linkage is most suitable for inhitory activity among the various sphingolipids tested to date.
The present study indicated that glycosphingolipid 7 inhibits the activation of Akt and Erk1/2, pathways involved in cell growth, concomitant with a decrease in cyclin D1 and CDK4. We previously described that the PI3-kinase-Akt pathway is activated by FAK in glioma cells. 17) Furthermore, we reported that the expression of cyclin D3 was increased by the overexpression of FAK in HL-60 cells. The PI3-kinase-Akt pathway is assumed to have a variety of functions in cell proliferation. 28) Furthermore, Akt's activation stabilizes cyclin D in the nucleus to stimulate cell growth.
29) The expression of cyclin D1 is also controlled by Ras and/or the Raf/Erk pathway. 30) The activation of Erk is reported to induce the activation of vascular endothelium growth factor (VEGF) 31) and calpain, factors important for cancer metastasis. 32) From these reports, glycosphingolipid 7 may suppress melanoma metastasis. The effect of glycosphingolipid 7 on the metastasis of melanoma cells needs to be studied further. The effect of glycosphingolipid 7 on the other cancer cell line such as T98G glioma cell line was tested and antiproliferative effect was observed (data not shown). In the present study, we demonstrated that the FAK, Akt, and Erk1/2 pathways were activated constitutively in melanoma cells and the activation was suppressed by glycosphingolipid 7.
A remaining issue is how glycosphingolipid 7 inhibits the activation of FAK. The ceramide structure and/or some terminal sugars are necessary for the inhibitory effect on melanoma proliferation. What then might the receptor for the glycolipid be? CD83, a receptor of sialic acid-binding glycoprotein, appears to be present on dendritic cells. 33) However, the glycolipid in this study did not contain sialic acid. Tolllike receptor 4 is activated by a-galactosylceramide, a bioactive glycolipid and immunomodulator isolated from Agelas mauritianu. 34) At present, further information is required to speculate on the receptor.
In conclusion, we described for the first time an inhibitory effect of glycosphingolipid 7 on the proliferation of melanoma cells through suppression of the activation of FAK-Akt and Erk1/2, the phosphorylation of pRb, and the expression of cyclinD1 and CDK4. Glycosphingolipid 7 might be a candidate for agent to inhibit melanoma cells.
